Organ and Tissue Transplantation and Alternatives
The global organ and tissue transplantation and alternatives market should reach $120.3 billion by 2024 from $89.9 billion in 2020 at a compound annual growth rate (CAGR) of 7.4% for the forecast period of 2019 to 2024.
- 26 data tables and 37 additional tables
- An overview of the global organ and tissue transplantation and alternatives market
- Estimation of the market size and analyses of market trends, with data from 2018 to 2019, estimates for 2020 and projection of CAGR through 2024
- Details about organ and tissue transplantation and alternatives, their pathophysiology and affects, and major advancement and latest trends
- A look at the regulatory scenarios and initiatives by government organization
- Analysis of current and future market dynamics and identification of key drivers, restraints and opportunities such as increasing incidence of organ donations, improved awareness about organ donations, side effects of organ and tissue transplantation and antibiotic resistance infections
- Coverage of emerging procedures and products in development and discussion on prevalence of major chronic diseases which initiates organ damage or donation
- Discussion on the role of the organ procurement organization and information on transplantation process and preparation and coverage of issues like black market donors
- Impact analysis of COVID-19 on organ and tissue transplantation and alternatives market
- Market share analysis of the key companies of the industry and coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies
- Company profiles of major players of the industry, including Abiomed Inc., Bayer AG, F. Hoffmann-La Roche & Co., Johnson & Johnson, Novartis AG, Pfizer Inc. and XVIVO Perfusion
This report offers forecasts, by product segment, from 2018 through 2024, including supporting analyses for projections. Product segments covered consist of the solid organ (e.g., kidneys, liver, heart-lung, pancreas, intestines) and the tissue transplantation (e.g., bone, skin, cornea, heart valve) markets, along with the pharmaceuticals that accompany each market.
Also included are experimental xenografts and artificial organs; tissue transplants; and cell transplants (e.g., bone marrow, cord blood, peripheral blood, islet cell). The report touches on the use of fetal cells, stem cells and altered cancer cells.
The arrangement of this report offers an overview of the key elements in the transplantation process: tissue typing, procurement and preservation, immunosuppressants for solid organ and tissue transplants, and postoperative monitoring. International markets are discussed, and information is provided on industry structure and the regulatory environment.
Within each section are discussions of commercialization opportunities for each segment of the market. New or emerging devices, techniques and pharmaceuticals are highlighted.
Profiles of leading companies involved with solid organ transplantation, tissue transplantation, and alternative technologies are included. The report provides information on company placement within the market and strategic analyses of the companies’ available and emerging products.
An appendix featuring various terms and processes used in transplantation is provided at the end of the report.
This report cites autologous products only in relation to their impact on the market for allografts. It does not include blood products, except for peripheral and umbilical cord blood as a source of stem cells.
By geography, the market has been segmented into the North America, Europe, Asia-Pacific, and Rest of the World regions. Detailed analysis of the market in major countries such as the U.S., Germany, the U.K., Italy, France, Spain, Japan, China, India, Brazil, Mexico, GCC countries and South Africa will be covered in the regional segment. For market estimates, data will be provided for 2019 as the base year, with estimates for 2020 and forecast value for 2024.
BCC Publishing Staff comprises expert analysts who are skilled in conducting primary research, secondary research and data analysis and have decades of combined experience covering a wide range of industries, including healthcare, advanced materials and emerging technologies. Collectively, the team represents a diverse set of educational achievements with individual graduate work completed in fields such as microbiology, electrical engineering, business administration and surgery, among others.
The global market for organ and tissue transplantation products and devices reached $56.9 billion in 2014. This market is estimated to grow at a compound annual growth rate (CAGR) of 7.1% to reach $64.4 billion by 2015 and nearly $90.6 billion by 2020.
- An overview of the global markets for organ and tissue transplantation and alternatives.
- Analyses of global market trends, with data from 2014, estimates for 2015 and projections of CAGR through 2020.
- Detailed examination of procurement and preservation, solid organ transplantation, tissue transplantation, immunosuppressives and other pharmaceuticals, post-transplantation concerns, as well as alternatives to transplantation.
- Coverage of post-transplant immunosuppression and monitoring methods and post-transplant drug regimens and patient and graft survival rates.
- In-depth analysis of the market's dynamics, specifically growth drivers, inhibitors, and opportunities
- Comprehensive profiles of major players in the industry.
The global market for transplantation products, devices, and pharmaceuticals was valued at nearly $54 billion in 2010 and is projected to grow at an 8.3% compound annual growth rate (CAGR) to reach $80 billion in 2015.
- The U.S. market for organ and tissue transplantation and alternatives was worth $18.9 billion in 2007. The market is projected to grow to $20.9 billion in 2008 and $28.2 billion in 2013, representing a compound annual growth rate (CAGR) of 6.1%.
- The solid organ segment has the largest share of the market, worth $9.7 billion in 2007 and an estimated $10.5 billion in 2008. This is expected to grow at a CAGR of 5.7% to reach $13.8 billion in 2013.
- Tissue transplantation generated $9.2 billion in 2007. This should increase to $10.4 billion in 2008 and $14.3 billion in 2013, for a CAGR of 6.5%.
The organ and tissue transplantation market in the U.S. is estimated at $11.7 billion in 2005 ad is expected to rise at an average annual growth rate (AAGR) of 5.2% to $15.1 billion by 2010.
The transplantation market is estimated at just under $5 billion in 2005 and is expanding at an AAGR of 4.8%.
The fastest growing sector is small bowel (intestine) transplantation. Kidney and liver transplantation will account for 78% of the total in 2005.
The U.S. tissue transplantation market totaled about $6.8 billion in 2005. It is projected to grow at an AAGR of 5.5%, to $8.9 billion in 2010.
Tissue and organ transplantation in the U.S. was a $17.3 billion market in 2002.
This is expected to grow 18% to $20.5 billion by 2007 at an average annual rate (AAGR) of 3.5%.
The fastest growing sector is small bowel transplantation.
Kidney transplantation accounted for 59% of U.S. organ transplants in 2002.